$3.8M
+$3.8M this year2 filings since 2026 · latest Equity filed
Hepion Pharmaceuticals is a New Jersey diagnostics company developing non-invasive liquid biopsy tests for the early detection and surveillance of hepatocellular carcinoma (HCC) in people living with cirrhosis. In 2026 it pivoted from liver-disease drug development to cancer diagnostics, assembling two complementary blood-based biomarker platforms: a clinically validated methylated DNA (mSEPT9) test and an in-licensed circulating tumor RNA (ctRNA) assay. The company is pursuing a staged commercialization path, launching through a CLIA laboratory before seeking FDA approval, and has identified partnership routes to accelerate market access. It trades publicly under the ticker HEPA.
What sets it apart
Pairs a near-commercial, clinically validated methylated DNA test with a next-generation ctRNA assay aimed specifically at hepatocellular carcinoma surveillance in cirrhotic patients, a setting where current standard-of-care surveillance is reported to miss up to 75% of early-stage cancers.
A blood-based liquid biopsy test that detects methylated SEPT9 DNA to identify early-stage hepatocellular carcinoma in high-risk patients with cirrhosis.
